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Abstract
For patients with chronic lung diseases, such as chronic obstructive pulmonary disease (COPD), exacerbations are life-
threatening events causing acute respiratory distress that can even lead to hospitalization and death. Although a great deal
of effort has been put into research of exacerbations and potential treatment options, the exact underlying mechanisms are
yet to be deciphered and no therapy that effectively targets the excessive inflammation is available. In this study, we report
that interleukin-1b (IL-1b) and interleukin-17A (IL-17A) are key mediators of neutrophilic inflammation in influenza-induced
exacerbations of chronic lung inflammation. Using a mouse model of disease, our data shows a role for IL-1b in mediating
lung dysfunction, and in driving neutrophilic inflammation during the whole phase of viral infection. We further report a
role for IL-17A as a mediator of IL-1b induced neutrophilia at early time points during influenza-induced exacerbations.
Blocking of IL-17A or IL-1 resulted in a significant abrogation of neutrophil recruitment to the airways in the initial phase of
infection or at the peak of viral replication, respectively. Therefore, IL-17A and IL-1b are potential targets for therapeutic
treatment of viral exacerbations of chronic lung inflammation
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Introduction
Chronic obstructive pulmonary disease (COPD) is currently
ranked the 4th leading cause of death worldwide by the World
Health Organization (WHO), and its incidence is increasing. The
main risk factor of COPD is exposure to tobacco smoke which
triggers a cascade of inflammatory pathways leading to disease
induction in susceptible people. Major hallmarks of the disease
pathology are the development of emphysema and chronic
bronchitis that lead to a progressive and irreversible airflow
limitation resulting in a continuous decline of lung function [1].
COPD severity has been associated with acute periods of disease
worsening [2,3], so-called exacerbations, a key factor in COPD
morbidity and mortality [4,5]. By causing acute respiratory
distress, they impact on the quality of patient’s health [6] and
are responsible for most hospital stays related to the disease [4].
Exacerbations are primarily caused by respiratory viral or
bacterial infections. Amongst those, viral-induced exacerbations
account for approximately half of the cases [7,8] and are
associated with more severe acute episodes and prolonged
recovery time [9–11]. The most common viral pathogen in
exacerbated patients is rhinovirus, followed by influenza virus,
RSV and coronavirus [7,8,10,12]. Due to targeted vaccination of
high risk groups, influenza infections occur less frequently in
COPD patients of westernized countries [11]. However, they
continue to be the predominant cause of viral exacerbations in
Hong Kong [13] and Singapore [14].
COPD exacerbations have been linked to excessive inflamma-
tory responses, including enhanced recruitment of inflammatory
cells [15] and upregulation of a variety of proinflammatory
mediators [16,17]. Nevertheless, the underlying mechanisms and
the most effective therapeutic strategies are still poorly understood
and first-line therapy still predominantly relies on corticosteroids
and bronchodilators [18], which are limited in their efficacy
[17,19]. Thus, the study of cellular and molecular mechanisms
leading to exacerbations is key for the identification of urgently
required therapeutic targets. One of the proinflammatory cyto-
kines that has been associated with COPD is IL-1b, a major player
in initiation and persistence of inflammation. In animal models
mimicking features of COPD, IL-1 has been shown to be key to
the induction of emphysema and inflammation [20–27]. Further-
more, its expression is significantly enhanced in COPD patients
during acute episodes of exacerbations [17,20,28,29]. Unraveling
the role of IL-1b in viral exacerbations might therefore not only
result in an overall better understanding of mechanisms of
exacerbations, but also indicate whether it qualifies as a valid
therapeutic target. A promising candidate for therapeutic inhibi-
tion of IL-1b signaling is one of its inhibitors, the interleukin-1
receptor antagonist (IL-1Ra) anakinra (Kineret, Amgen), which
has been used effectively in treatment of rheumatoid arthritis.
PLOS ONE | www.plosone.org 1 June 2014 | Volume 9 | Issue 6 | e98440
In order to investigate the role of IL-1b during COPD
exacerbations we utilized a model of LPS and elastase induced
chronic lung inflammation, followed by infection with influenza in
wild type or IL-1b deficient mice. We found that IL-1b was a key
driver of pulmonary inflammation, primarily concerning recruit-
ment of neutrophils and lung dysfunction. IL-1b driven neutro-
philia was mediated by IL-17A in the initial phase of viral
infection, but became independent of IL-17A during the peak
phase of viral replication. Treatment with the IL-1Ra, anakinra,
proved efficient in reducing neutrophilic inflammation at the peak
of viral replication while blocking of IL-17A abrogated neutro-
philia in the early phase of viral infection. Taken together our data
indicate that blockade of IL-1b and IL-17A could be valid
therapeutic approaches for treatment of virus-induced COPD
exacerbations.
Materials and Methods
Ethics Statement
All animal experiments were performed according to institu-
tional guidelines and Swiss federal and cantonal laws on animal
protection. Animal experiments were approved by the following
ethical committee: Service de la consommation et des affaires
ve´te´rinaires, Affaires ve´te´rinaires, Canton de Vaud, Switzerland
(permit numbers 2283 and 2216).
Mice
C57BL/6 or BALB/c mice were between 8–12 weeks of age
and were purchased from Charles River Laboratories. IL-1b
deficient mice on C57BL/6 background were received from Prof.
Iwakura [30], Tokyo University of Science, Japan, and bred in
house.
LPS/elastase Exposure and Viral Infection
Mice were exposed intranasally to a mixture of 7 mg LPS from
E. coli O26:B6 (Sigma-Aldrich) and 1.2 U porcine pancreatic
elastase (EPC) in a total volume of 100 ml, and treated once per
week for four consecutive weeks (Figure 1A). Control mice were
treated with PBS. Two weeks after the last LPS/elastase challenge,
mice were infected with 250 PFU influenza A virus, strain PR8
(A/Puerto Rico8/34, H1N1, Viropur). The virus was adminis-
tered intranasally in a total volume of 50 ml PBS; control mice
received only PBS. For all intranasal administrations C57BL/
6 mice were anesthetized by intraperitoneal injection of
54.17 mg/kg Ketamin (Ketasol-100, Graeub) and 1.28 mg/kg
Xylazin (Xylasol, Graeub) and BALB/c mice with 78 mg/kg
Ketamin and 1.93 mg/kg Xylazin.
Histology and Quantification of Damage
Lungs were inflated with 1 ml 10% formalin, embedded into
paraffin and stained with hematoxylin and eosin. Stained slides
were analyzed by light microscopy. Pulmonary emphysema was
quantified using Image J software by measuring the mean linear
intercept for airspace enlargement and destruction index for
alveolar wall destruction. 10 fields of view at 20X magnification
per section of lung were used for quantification as described
previously [31,32].
Quantification of Airway Inflammation
Airway cells were recovered by bronchoalveolar lavage and
either analyzed by flow cytometry as described below or spun onto
slides for differential cell counts. Slides were stained with Diff-Quik
(Dade) and counts were performed according to standard criteria.
Assessment of Pulmonary Resistance
Total lung resistance was measured using the whole body
restrained plethysmograph system flexiVent from Scireq. Mice
were anesthetized by intramuscular injection of 100 mg/kg
ketamine (Ketasol-100, Graeub) and intraperitoneal injection of
50 mg/kg pentobarbital (Esconarkon, Streuli Pharma). Subse-
quently, mice were tracheotomized and mechanically ventilated at
a rate of 450 breaths/min and a tidal volume of 10 ml/kg
bodyweight.
Flow Cytometry
Single cell suspensions from the whole lung including airways
and trachea were obtained by digestion with 2 mg/ml Collagenase
IV (Invitrogen) and 50 U/ml DNaseI (Roche). Neutrophils and
monocytes in lung and bronchoalveolar lavage fluid were
distinguished by staining with CD11c APC-Cy7, CD11b PerCP-
Cy5.5, Ly-6G Biotin, Ly-6C Pacific Blue, Streptavidin PE-Cy7.
Neutrophils were defined as CD11c2 CD11b+ Ly-6C+ Ly-6G+
and inflammatory monocytes as CD11c2 CD11b+ Ly-6C+ Ly-
6Glow2intermediate as precised in detail in Figure S1A.
To analyze IL-17A production, cells from lung digests were
stimulated with 1027 M PMA, 1 mg/ml Ionomycin and
261026 M Monensin for 4 h at 37uC (indicated chemicals were
purchased from Sigma-Aldrich). Subsequently, cell subsets were
distinguished by surface staining for CD4 PerCP-Cy5.5, CD8b
FITC, cd TCR Biotin, CD3 Pacific Blue, Streptavidin PE-Cy7
(Figure S1B) and IL-17A production was characterized by
intracellularly staining with IL-17A Alexa700 after fixation with
BD lysis buffer (BD Biosciences). All antibodies were purchased
from Biolegend. Stained cells were acquired on a BD FACS
CANTO or BD FACS LSRII and analyzed by using FlowJo
software (Tree Star).
Antibodies for in vivo Studies
For neutralization of IL-17A, mice were treated with 250 mg of
anti-IL-17A (clone 17F3) or the corresponding isotype control
antibody (clone MPOC-21) from BioXCell. The clone 17F3
uniquely reacts with the IL-17A and no other IL-17 isoform [33].
Antibodies were administered intraperitoneally one day before
viral infection and two days post infection.
To block IL-1b signaling mice received 200 mg of the
interleukin-1 receptor antagonist (IL-1Ra) anakinra (Kineret,
Amgen) twice daily while control mice received only PBS.
Anakinra was kindly provided by Prof. Alexander So (Centre
Hospitalier Universitaire Vaudois, Lausanne, Switzerland) and
Mme Ghislaine Aubel (Centre Hospitalier Universitaire Vaudois,
Lausanne, Switzerland).
Quantitative Real-time PCR
Total RNA was isolated from lung and trachea with TRI
reagent (Molecular Research). All RNA samples were checked for
purity using a NanoDrop 1000 spectrophotometer (Thermo
Scientific) and met standard quality criteria. RNA was subse-
quently transcribed into cDNA by the iScript cDNA Synthesis kit
(Bio-Rad) and quantitative real-time PCR was performed accord-
ing to the manufacturer’s instructions utilizing the SsoAdvanced
SYBR Green Supermix from Bio-Rad. Expression was deter-
mined by comparative delta-threshold cycle method using
GAPDH as a comparator. The following primers were used:
GAPDH forward 59-GGG TGT GAA CCA CGA GAA AT-39,
GAPDH reverse 59-CCT TCC ACA ATG CCA AAG TT-39;
CXCL1 forward 59-GCC TAT CGC CAA TGA GCT G-39,
CXCL1 reverse 59-ATT CTT GAG TGT GGC TAT GA-39;
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CXCL2 forward 59-AGT GAA CTG CGC TGT CAA TG-39,
CXCL2 reverse 59-GCC CTT GAG AGT GGC TAT GAC-39;
CXCL5 forward 59-AGC ATC TAG CTG AAG CTG CCC C-
39, CXCL5 reverse 59-CCG TAG GGC ACT GTG GAC CTG-
39; G-CSF forward 59-TGA CAC AGC TTG TAG GTG GC-39,
G-CSF reverse 59-TCC TGC TTA AGT CCC TGG AG-39; IL-6
forward 59-TTC CAT CCA GTT GCC TTC TTG-39, IL-6
reverse 59-TCA TTT CCA CGA TTT CCC AGA G-39; IL-17A
forward 59-ACC CTG GAC TCT CCA CCG CAA-39, IL-17A
reverse 59-GGT GGT CCA GCT TTC CCT CCG-39; influenza
matrix protein forward 59-GGA CTG CAG CGT AGA CGC
TT-39, influenza matrix protein reverse 59-CAT CCT GTT GTA
Figure 1. Model of chronic lung inflammation in BALB/c and C57BL/6 mice. BALB/c or C57BL/6 mice were exposed to LPS/elastase (L/E) or
PBS once per week for four consecutive weeks as depicted in Figure 1A. Disease severity was determined one week after the last LPS/elastase
challenge. (B) Histological sections of lungs were stained with hematoxylin and eosin (H&E). (C) Destructive index (DI) and mean linear intercept (Lm)
were scored from histological sections. (D) Cellular influx into airways was assessed by differential cell counts. All data are representative of at least
two independent experiments (n = 3–5), error bars indicate standard error of the mean (s.e.m).
doi:10.1371/journal.pone.0098440.g001
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TAT GAG GCC CAT-39; TNFa forward 59-GCC AGG AGG
GAG AAC AGA AAC-39, TNFa reverse 59-GCC AGT GAG
TGA AAG GGA CAG-39.
ELISA
To determine cytokine levels whole lung and trachea were
collected and stored in protease inhibitor solution (Roche) at 2
20uC until use. Tissue homogenate was prepared using a
TissueLyser (Qiagen). IL-1b protein was determined using the
mouse IL-1b ELISA kit Ready-SET-Go! from eBioscience by
following the manufacturer’s instructions. IL-6 and TNFa were
measured in a sandwich ELISA using 2.5 mg/ml anti-mouse IL-
6 or TNFa (Biolegend) for coating. Bound protein was detected by
1 mg/ml biotin labeled anti-IL-6 or anti-TNFa antibody (Biole-
gend) and subsequent incubation with alkaline phosphatase
conjugated streptavidin (Biolegend). Plates were developed using
the substrate p-Nitrophenyl phosphate (Sigma-Aldrich) and OD
was measured using an ELISA reader (Biotek).
Statistical Analysis
Statistical significant differences were assessed using the
Student’s t test (two tailed, unpaired). P-values below 0.05 were
considered significant and were depicted with p#0.05 (*), p#
0.005 (**), p#0.0005 (***). Standard error of the mean was
applied.
Results
Influenza-induced Exacerbations are Characterized by
Neutrophilic Inflammation and Increased Airway
Resistance
COPD is a heterogeneous disease in humans but core features
of its pathology can be reproduced in mice by repetitive exposure
to lipopolysaccharide (LPS) and elastase [34]. LPS is a bacterial
endotoxin present in tobacco smoke [35,36], the predominant risk
factor of COPD. It has been shown to cause inflammation, and
particularly when co-administered with elastase, chronic emphy-
sema-like changes develop in mouse lungs [34]. As such, we
exposed mice once a week for 4 consecutive weeks to a mixture of
7 mg LPS and 1.2 U porcine pancreatic elastase via the intranasal
route, as depicted in Figure 1A. By this we induced strong
emphysema (Figure 1B,C) and sustained pulmonary inflammation
(Figure 1B,D) in BALB/c and C57BL/6 mice. The development
of emphysema was scored by increases in the mean linear intercept
and the destructive index (Figure 1C) from lung histology. In
addition, we observed a strong airway inflammation, mainly
driven by neutrophils and lymphocytes (Figure 1D). Both,
emphysema and inflammation, remained above baseline levels
for at least 2 months (data not shown). Thus, the response induced
by repeated challenges with LPS/elastase resembled the pathology
of COPD. As the disease severity was more pronounced in the
BALB/c strain (Figure 1B–D), all experiments performed in wild
type mice were conducted in BALB/c mice.
To study viral-induced exacerbations, mice were infected with
influenza virus 2 weeks after the last LPS/elastase challenge, when
the acute inflammation caused by LPS/elastase exposure had
subsided (Figure 2A). The peak of viral replication was reached
5 days after the infection (Figure 2B) and was followed by a rapid
decline in viral titers (Figure 2B) until complete viral clearance at
day 9 post infection (data not shown). The efficiency of the
influenza infection was strikingly reduced in mice pretreated with
LPS/elastase compared to naı¨ve mice, as revealed by significantly
lower viral titers at the peak of viral infection, day 5 and day 7 post
infection (Figure S2) which was also reflected by reduced amounts
of viable virus in the lung on day 5 (data not shown). This is likely
to be due to the development of a polyclonal antibody response
observed upon LPS/elastase treatment ([37,38] and data not
shown). Thus, the response to the influenza infection was not
comparable between LPS/elastase pretreated and naive mice, and
was therefore not included in the remainder of the study.
Invasive measurements of pulmonary resistance in LPS/elastase
pretreated mice revealed a viral-induced acute exacerbation of
airway dysfunction (Figure 2C). Pulmonary resistance can be
influenced by a variety of factors, of which the severity of
inflammation is likely to play one of the key roles during
exacerbations. In line with this we detected a strong inflammatory
response upon infection with influenza virus associated with an
augmented absolute number of cells infiltrating into the airways
and the lung (Figure 2D). The cells were primarily neutrophils
(Figure 2E, Figure S3A) and inflammatory monocytes (Figure 2F,
Figure S4A). The peak of neutrophilic inflammation was reached
at day 5 post infection and neutrophil numbers declined
afterwards (Figure 2E, Figure S3A), directly correlating with the
kinetics of viral replication (Figure 2B). In line with this we
observed increased expression of the proinflammatory cytokines
IL-6 and TNFa peaking at day 3 or 5 post infection, respectively,
and subsiding at day 7 after the infection (Figure 2G).
Emphysematous damage upon LPS/elastase treatment also
resulted in an increase in the lung compliance. However the acute
inflammatory changes induced by influenza infection had no
impact on the increase in lung compliance (data not shown).
Acute pulmonary dysfunction, neutrophilic inflammation and
enhanced levels of proinflammatory cytokines such as IL-6 and
TNFa have all been observed during exacerbations of COPD
patients, indicating that the viral-induced inflammation in our
mouse model is in line with that seen in humans.
IL-1b Contributes to Lung Dysfunction and Pulmonary
Inflammation during Influenza Infection of LPS/elastase
Treated Mice
IL-1 has previously been shown to be a driving factor in the
development of emphysema and inflammation in animal models
of COPD [20–27]. As we observed an increase of IL-1b protein in
the lungs of LPS/elastase treated mice upon influenza infection
(Figure 3A), we hypothesized that it also promotes innate immune
responses and influences pulmonary function during exacerba-
tions. Consequently, we exposed IL-1b deficient and C57BL/
6 wild type mice to LPS/elastase and infected them with influenza
virus as described above. The C57BL/6 strain showed similar
kinetics of neutrophil and inflammatory monocyte recruitment
upon viral exacerbation as observed for the BALB/c mice
(Figure 3D, Figure S3B, S4B).
Of note, viral replication was not altered in IL-1b deficient mice
(Figure 3B), demonstrating that any effects seen in the absence of
IL-1b were not due to differences in the infection rate. C57BL/
6 wild type mice exhibited a smaller change in pulmonary
resistance in response to viral infection (Figure 3C) in comparison
to BALB/c mice (Figure 2C), with a slight increase at day 1 post
infection (Figure 3C). Nevertheless, pulmonary resistance in mice
lacking IL-1b was significantly reduced already after LPS/elastase
exposure alone (Figure 3C), thus supporting the described role for
IL-1b in the development of chronic lung disease [20–27].
Furthermore, pulmonary resistance in IL-1b-deficient mice was
also completely unaffected by the viral challenge (Figure 3C). We
did not detect any impact of IL-1b on inflammatory monocytes
(Figure S4B); however, we found a decreased frequency and
number of neutrophils in non-infected IL-1b deficient mice upon
exposure to LPS/elastase (Figure 3D, Figure S3C). Similarly, the
Viral Exacerbation of Chronic Lung Inflammation
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recruitment of neutrophils to the airways and lung following viral
infection was also significantly abrogated in the absence of IL-1b
(Figure 3D, Figure S3C). We observed significantly lower
frequencies and absolute numbers of neutrophils including during
the peak of neutrophil infiltration and viral replication at day
5 post infection (Figure 3D, Figure S3C). Nevertheless, the control
of the virus was unaffected as displayed by unaltered viral titers
(Figure 3B).
Considering its strong impact particularly upon neutrophils, we
sought to address the mechanisms through which IL-1b mediated
this neutrophilic inflammation. Expression of the main neutrophil
chemoattractants CXCL1, CXCL2, and CXCL5 were induced
upon influenza infection, but were unaffected by IL-1b (Figure
S5). In addition we did not detect any influence of IL-1b or the
viral infection on the expression of G-CSF (Figure S5). Given there
is substantial redundancy in neutrophil chemoattractants we thus
next looked upstream at the proinflammatory cytokines IL-17A,
IL-6, and TNFa, which can all stimulate neutrophilic inflamma-
tion by inducing chemotactic, growth or survival factors
[16,39,40]. As expression of IL-6 and TNFa were induced in
our mouse model upon influenza infection (Figure 2G), we
hypothesized that IL-1b drove the observed inflammation by
altering their production. The peak expression of IL-6 and TNFa
upon influenza infection was reached faster in C57BL/6 wild type
mice at day 1 post infection (Figure 2G) as compared to day 3 in
BALB/c mice (Figure 3E), and thus coincided with the earlier
response in pulmonary resistance observed in the C57BL/6 strain
(Figure 3C). IL-6 protein levels followed similar kinetics in both
mouse strains (Figure S6A,B), while TNFa protein production was
below the sensitivity limit of our assay. However, lack of IL-1b did
not impair the expression and production of IL-6 (Figure 3E,
Figure S6B) and in fact increased the expression of TNFa
(Figure 3E). We therefore focused on IL-17A, a proinflammatory
cytokine that has been shown to be elevated in COPD patients
[41,42] and whose induction partially depends on IL-1b [43–45].
We found significantly reduced expression levels of IL-17A in lung
Figure 2. Influenza infection induced exacerbation of established disease in LPS/elastase exposed mice. (A) Experimental protocol of
influenza-induced exacerbation of LPS/elastase exposed mice. Control mice (indicated as day 0 in the following) were pre-exposed to LPS/elastase as
were their infected counterparts, but challenged only with PBS instead of influenza virus. (B) Viral load of whole lung including airways and trachea
was determined by quantitative real-time PCR at the indicated time points post infection or in non-infected mice (day 0) as control, respectively.
Expression of influenza matrix protein was normalized to GAPDH. (C) Airway and tissue resistance was assessed by invasive plethysmography. (D)
Absolute number of cells in the airways and lung was determined, and (E) the proportion of neutrophils and (F) inflammatory monocytes recruited to
airways and lungs upon infection (day 3–7) or PBS challenge (day 0) was analyzed by flow cytometry. (G) Expression of IL-6 and TNFa was assessed by
real-time PCR and normalized to GAPDH. (B)–(G) Experiments were performed in BALB/c mice and results are representative of at least two
independent experiments (n = 4–5). Error bars represent s.e.m.; i.n. (intranasal).
doi:10.1371/journal.pone.0098440.g002
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homogenate in the absence of IL-1b, in both non-infected as well
as influenza-infected LPS/elastase exposed mice (Figure 3F). IL-
17A production was significantly reduced in the predominant
cellular sources of IL-17A, such as the CD4+ T cells and the cd T
cells in IL-1b deficient mice (Figure 3G). Further sources of IL-
17A such as CD3+ CD42 CD82 cdTCR2 cells that might
comprise NKT cells, and CD32 cells also showed reduced levels of
IL-17A in the absence of IL-1b (Figure S7A). However, even in
the wild type animals these cells represented a very minor
population of cells relative to the IL-17A-producing T cells (Figure
S7A). Taken together our data showed that in addition to
contributing to lung dysfunction, IL-1b played a key role in
driving neutrophilic inflammation during influenza-induced exac-
erbations, an effect that was tightly linked to IL-17A expression.
Initial Neutrophil Recruitment during Exacerbations is
Mediated by IL-17A can be Abrogated by Treatment with
Neutralizing Antibodies
To assess whether IL-17A was indeed a mediator of IL-1b
driven neutrophilia we neutralized IL-17A during influenza
infection of LPS/elastase treated mice. Neutralization assays were
performed in BALB/c mice, which exhibited a similar induction of
IL-17A as C57BL/6 mice (Figure S7B). Mice received either an
IL-17A neutralizing antibody or an isotype control antibody one
day before and two days after the viral infection (Figure 4A). IL-
17A neutralization did not impact on the control of viral
replication, as viral burden was comparable to the isotype control
treated animals (Figure 4B). We found that influenza-induced
neutrophil recruitment to the airways and lung was indeed entirely
attenuated 24 h after the infection in absence of IL-17A
(Figure 4C, Figure S3D). However, neutrophils infiltrated into
the lung and airways during the later stages of infection (day 3 and
5 respectively) to finally reach the same frequencies as in mice
Figure 3. IL-1b mediated airway resistance, neutrophilic inflammation and IL-17A expression during influenza-induced
exacerbations of COPD. Exacerbation of COPD in C57BL/6 mice was induced as depicted in Figure 2A. (A) IL-1b protein in whole lung including
airways and trachea following influenza infection (day 1–5) or PBS challenge (day 0) was assessed by ELISA. (B) Viral load in whole lung and trachea of
wild type or IL-1b deficient animals was determined by quantitative real-time PCR and normalized to GAPDH. (C) Airway and tissue resistance was
measured by invasive plethysmography at indicated time points after infection. (D) The proportion of neutrophils in the airways and lung was
determined by flow cytometry. Data are pooled from two independent experiments (n = 4–5). (E) Expression of IL-6, TNFa, and (F) IL-17A was assessed
by quantitative real-time PCR and normalized to GAPDH. (G) Proportion of IL-17A positive CD4+ T cells or cd T cells was determined by flow cytometry
after restimulation in vitro. All data are representative of at least two independent experiments (n = 4–5) and mean 6 s.e.m. is shown.
doi:10.1371/journal.pone.0098440.g003
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treated with the isotype control (Figure 4C, Figure S3D); thus
indicating that IL-17A was only required for the initial but not for
the later recruitment of neutrophils. Hence, IL-1b driven
neutrophilia during influenza infection of LPS/elastase exposed
mice was mediated by IL-17A in the early phase of infection, but
became independent of IL-17A.
Treatment with Human Recombinant IL-1Ra Impairs
Neutrophil Recruitment at the Peak of Viral Replication
Our data showed that a constitutive lack of IL-1b substantially
impaired neutrophil infiltration into the airways and lung during
influenza-induced exacerbations of chronic lung inflammation.
Thus, we sought to assess whether it is sufficient to block IL-1b
signaling only during the course of infection, an important
determinant regarding a potential therapeutic intervention.
Accordingly, recombinant IL-1Ra (Anakinra) or PBS was admin-
istered twice daily, starting two days prior to the viral infection
(Figure 5A). Mice receiving Anakinra displayed an impaired early
control of viral infection leading to a higher viral burden at day
3 post infection, although viral titers rapidly declined afterwards to
levels similar to non-treated mice at day 7 post infection
(Figure 5B), and virus was completely cleared at day 9 post
infection (data not shown). Treatment with Anakinra was efficient
in reducing neutrophil frequencies and numbers in the airways at
day 5 post infection, the peak of neutrophilic infiltration and viral
replication (Figure 5C, Figure S3E). We did not observe an effect
of Anakinra on the recruitment of inflammatory monocytes
(Figure S4C). Similarly, we did not detect significant changes in
lung function upon the treatment with Anakinra (data not shown).
In conclusion our data demonstrated that IL-1b influenced
neutrophilic inflammation during influenza-induced exacerbation
of chronic lung inflammation in mice throughout the entire phase
of viral replication. Neutrophil recruitment was mediated by IL-
17A in the first 24 h following viral challenge and could efficiently
be blocked in the early phase of infection by antibodies
neutralizing IL-17A. During the peak of inflammation and viral
replication, IL-1b driven neutrophilia was independent of IL-17A,
but could be significantly reduced by treatment with the IL-1Ra
anakinra (Figure 6).
Discussion
In addition to a constant disease burden, COPD patients suffer
from episodes of acute symptom worsening causing a rapid decline
in respiratory function that can necessitate hospitalization and
even lead to death [46]. Indeed, a meta-analysis study estimated a
case-fatality rate of 15.6% following hospitalization due to an
exacerbation [47]. As there is a clear need to understand the
mechanisms driving exacerbations and responsiveness to therapy,
we examined viral-induced exacerbations in mice. In our model
(Figure 2A), mice developed a strong inflammatory response
characterized by a neutrophilic infiltrate into the airways and lung
(Figure 2E), enhanced expression of proinflammatory cytokines
such as TNFa and IL-6 (Figure 2G), and impairment in lung
function (Figure 2C). Decline in lung function and neutrophil
accumulation are characteristic of exacerbations in humans [48–
50], and elevated levels of TNFa and IL-6 have similarly been
measured in the sputum of patients undergoing an exacerbation
[17,51]. Thus, our mouse model reflects key pathological
characteristics of COPD exacerbations in humans.
Figure 4. IL-17A mediated neutrophilic inflammation during the initial phase of influenza-induced exacerbation. (A) BALB/c mice
were treated with anti-IL-17A (a-IL-17A) or isotype control antibody one day prior and two days after infection with influenza virus (day 1–5 post
infection) or PBS challenge (day 0). (B) Viral load was measured by quantitative real-time PCR and normalized to GAPDH. (C) The proportion of
neutrophils in airways and lung were assessed by flow cytometry. Two representative FACS plots of airway neutrophilia at day 1 after infection are
shown as well as the accumulated data. FACS plots show Ly-6C versus Ly-6G expression of CD11c2 CD11b+ pre-gated cells and indicate the
frequency of neutrophils of all live cells. Data are representative of two independent experiments (n = 4–5), error bars indicate s.e.m; i.n. (intranasal);
p.i. (post infection); ctrl (control).
doi:10.1371/journal.pone.0098440.g004
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Given the significant differences in susceptibility between the
PBS treated and LPS/Elastase treated mice (Figure S2 and data
not shown) which might be due to the development of a polyclonal
B-cell response upon LPS/Elastase administration, we believe that
conclusions can only be drawn from the comparison between
stable disease versus episodes of exacerbation. Notably, this is also
supported by findings in cigarette smoke (CS) models of
pulmonary inflammation where CS exposed mice showed a
considerably altered response to influenza infection [37] as well as
the accelerated clearance of Haemophilus influenza [38] in compar-
ison to control mice.
In this study we specifically focused on the role of the
proinflammatory cytokine IL-1b. IL-1 signaling has been shown
to be essential for the recruitment of neutrophils in other mouse
models mimicking the pathology of stable COPD, such as
exposure to cigarette smoke [20,21,23,26] or to elastase alone
[22]. Building upon these studies we found that during influenza-
induced exacerbations, pulmonary accumulation of neutrophils
was also driven by IL-1b (Figure 3D, Figure S3C). Our data is in
line with results from a study of Botelho et al. [20] who
investigated IL-1 in a mouse model of acute cigarette smoke
exposure. They found that interleukin-1 receptor (IL-1R)
deficiency led to a reduction of neutrophils following infection
with influenza and that this effect was independent of IL-1a. One
could therefore speculate that IL-1b may play a critical role in
neutrophil recruitment in their model as well.
IL-17A, a cytokine that plays a central role in amplifying
inflammatory cascades by inducing a variety of chemokines and
cytokines, has also been reported to contribute to the development
of emphysema [52,53] and to the immunopathology following
influenza infections [54]. In line with this, we found that IL-17A
mediated early inflammation in our model of influenza-induced
exacerbations of chronic lung disease (Figure 4C). Our data
showed that IL-1b driven neutrophil recruitment during the first
24 h of infection was mediated by lL-17A, while it became
independent of IL-17A at later time points during the exacerba-
tion. We found that in the absence of IL-1b the expression of IL-
17A was completely abrogated upon LPS/elastase exposure as
well as during exacerbations (Figure 3F), thus demonstrating that
IL-1b is required for the induction of IL-17A. IL-17A expression
was induced by LPS/elastase exposure alone, and levels were
maintained throughout the viral-induced exacerbation
(Figure 3F,G); however, while IL-1b levels increased during the
later phase of infection (Figure 3A), IL-17A expression surprisingly
remained unaltered and even decreased at the peak of viral
replication (Figure 3F). Nevertheless, we could block the recruit-
ment of neutrophils at early time points following the influenza
infection by neutralizing IL-17A (Figure 4C). During the peak of
viral replication, and thus a more severe state of inflammation, IL-
Figure 5. Treatment with Anakinra reduced neutrophil recruitment to the airways at the peak of viral-induced inflammation. (A)
BALB/c mice received Anakinra or PBS twice every day, starting two days prior to the viral infection and until mice were sacrificed. (B) Viral load was
determined by quantitative real-time PCR and normalized to GAPDH. (C) Proportion of neutrophils recruited to the airways following influenza
infection (day 1–5) or PBS challenge (day 0) was assessed by flow cytometry. Two representative FACS plots of each group at day 5 after infection are
shown as well as the plotted data. FACS plots show Ly-6C versus Ly-6G expression of CD11c2 CD11b+ pre-gated cells and indicate the frequency of
neutrophils of all live cells. Data are representative of two independent experiments (n = 4–5), error bars indicate s.e.m; i.n. (intranasal); p.i. (post
infection); ctrl (control).
doi:10.1371/journal.pone.0098440.g005
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17A neutralization could not prevent neutrophil influx. This might
be due to an induction of cytokines during the progression of the
infection, which could overcome the effect of IL-17A. Therefore,
treatment with anti-IL-17A seems to be favorable in the early
phases of exacerbations while blocking IL-1b might be more
advantageous during the ongoing infection. Whether these
findings translate into a clinical setting remains to be investigated.
Keeping in mind that neutrophil recruitment is elevated in the
vast majority of cases of COPD exacerbations regardless of their
etiology [7], and furthermore that the increase of neutrophils in
the sputum correlates with exacerbation severity [7], attenuating
neutrophilia could be beneficial in patients undergoing a viral-
induced exacerbation. Current treatment relies mainly on
corticosteroids and bronchodilators that have been shown to
reduce the frequency of exacerbations [55–57], but have no
positive effect on an ongoing episode of exacerbation. Indeed, no
reduction in the inflammatory response including neutrophil influx
in mice and cytokine expression in humans could be achieved by
treatment with steroids during COPD exacerbations [17,19]. In
contrast, corticosteroids have been shown to actually support
neutrophil survival [58,59]. Moreover, treatment with corticoste-
roids, efficient in reducing IL-1b levels in stable COPD, did not
affect the amount of IL-1b protein in exhaled breath condensate
during exacerbations [17]. As blocking of either IL-17A
(Figure 4C) or IL-1b (Figure 3D, Figure S3C) efficiently reduced
neutrophilic inflammation during viral exacerbation, these two
molecules could be considered potential targets for therapeutic
intervention. Given the redundancies in these two inflammatory
pathways, a combination therapy of anti-IL-17A and anti-IL-1b
may prove more beneficial in improving lung function.
Within the context of targeting IL-17A or IL-1b in the clinic,
one has to keep in mind that altering proinflammatory immune
responses harbors the risk of interfering with the control of acute
infection and of susceptibility to opportunistic infections. To
shorten the duration of intervention and thereby reducing the risk
of prolonged or secondary infections, we treated mice directly
before and during the viral infection with anti-IL-17A (Figure 4A)
or IL-1Ra (Figure 5A). This was sufficient to abrogate neutrophil
recruitment at the indicated time points. Furthermore, neutraliz-
ing IL-17A did not promote elevated viral replication (Figure 4B).
Treatment with IL-1Ra, and thereby blocking both IL-1a and IL-
1b, led to increased viral titers in the initial phase of infection
(Figure 5B), whereas the absence of IL-1b alone did not affect viral
replication (Figure 3B). It is therefore likely that in our model the
initial control of the virus might be mediated rather by IL-1a than
by IL-1b. This is in line with data from Botelho et al. [20], who
found similarly elevated viral titers upon neutralization of IL1-a as
in the complete absence of IL-1R. Our data thus suggest that
targeting specifically IL-1b, and not its receptor, would be
favorable in a therapeutic application. However, as treatment
with Anakinra did not interfere with final viral clearance it still
could be considered as a therapeutic approach with the additional
advantage of already being used in the clinic for other indications.
Taken together our data demonstrated that blocking of IL-17A
or IL-1b signaling during influenza-induced exacerbations dimin-
ished neutrophilic infiltration at distinct phases of infection.
Figure 6. Neutrophilic inflammation during influenza-induced exacerbation of COPD is mediated by IL-1b and IL-17A. (A) In the initial
phase of viral replication, at 24 h following the infection, IL-1b-induced IL-17A caused the recruitment of neutrophils to the airways and lung. (B) At
the peak of viral replication, day 5 post infection, neutrophilia became independent of IL-17A, but was still mediated by IL-1b. Blocking of IL-17A or
IL-1b abrogated neutrophilic inflammation in the early phase of the infection or at the peak of viral replication, respectively.
doi:10.1371/journal.pone.0098440.g006
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Whether those mechanisms apply also to other respiratory viral
infections remains to be elucidated, however is plausible given the
common early inflammatory pathways induced by respiratory
viral infections. Overall, blockade of IL-17A and IL-1b could be
valuable therapeutic options for future treatment of viral induced
exacerbations of chronic lung inflammation.
Supporting Information
Figure S1 Identification of cell subsets in airways and lung by
flow cytometry. Cells from lung digest or bronchoalveolar lavage
of the airways were characterized by flow cytometry. (A)
Neutrophils were distinguished by absence of CD11c, and by
high expression of CD11b, Ly-6G, and Ly-6C, while inflamma-
tory monocytes were defined as CD11c2 CD11b+ Ly-6C+ Ly-
6Glow2intermediate. (B) CD4+ T cells were characterized by positive
staining for CD4 and cd T cells were distinguished by expression
of CD3 and the cd TCR. Gates were set according to fluorescence
minus one controls where applicable.
(TIF)
Figure S2 Impaired infection by influenza virus in mice
pretreated with LPS/elastase. Naı¨ve or LPS/elastase treated
BALB/c mice were infected with influenza virus as described in
the materials and methods. The viral load was determined in
whole lung including airways and trachea by quantitative real-time
PCR and normalized to GAPDH. Data are representative of three
independent experiments (n = 4–5).
(TIF)
Figure S3 Absolute numbers of neutrophils during exacerba-
tions reflect the same results as neutrophil frequencies. Absolute
numbers of neutrophils recruited to the airways and lungs upon
infection (day 1–7) or PBS challenge (day 0) of LPS/elastase
pretreated mice were calculated according to cell frequencies
determined by flow cytometry (Figure 1–4) and total cell influx.
Absolute numbers of neutrophils are shown for (A) BALB/c wild
type mice, (B) C57BL/6 wild type mice, (C) IL-1b deficient mice,
(D) mice treated with anti-IL-17A (a-IL-17A) or isotype control
antibody, and (E) for mice treated with anakinra or PBS
respectively. (D) +(p = 0.06). (A)–(B), (D)–(E) Results are represen-
tative of at least two independent experiments (n = 4–5). (C) Data
are pooled from two independent experiments (n = 4–5). Error
bars represent s.e.m.
(TIF)
Figure S4 Inflammatory monocytes were induced during the
exacerbation but unaffected by IL-1b deficiency. Total numbers of
inflammatory monocytes recruited to airways and lungs were
calculated according to cell frequencies determined by flow
cytometry and total cell influx. Inflammatory monocyte influx is
shown for (A) BALB/c wild type mice, (B) IL-1b deficient mice,
and (C) for mice treated with anakinra or PBS, respectively. (A)–
(C) Results are representative of at least two independent
experiments (n = 4–5). Error bars represent standard error of the
mean (s.e.m.).
(TIF)
Figure S5 IL-1b did not influence the expression of the
neutrophil chemoattractants CXCL1, CXCL2, CXCL5, or G-
CSF. Expression of CXCL1, CXCL2, CXCL5, and G-CSF in
whole lung including airways and trachea of C57BL/6 wild type
and IL-1b deficient mice was assessed by quantitative real-time
PCR and normalized to GAPDH. For CXCL1, CXCL2 and
CXCL5 data are pooled from two independent experiments
(n = 4–5), for G-CSF data are representative of two independent
experiments (n = 4–5). Error bars indicate s.e.m. Filled circles
indicate wild type, open circles IL-1b deficient mice.
(TIF)
Figure S6 IL-6 protein followed similar kinetics in C57BL/6
and BALB/c mice and was unaffected by IL-1b. IL-6 protein in
lung homogenate following viral infection of LPS/elastase exposed
mice was determined by ELISA in (A) BALB/c and (B) C57BL/
6 wild type mice as well as in (B) IL-1b deficient mice. Results are
representative of (A) two and (B) three independent experiments
(n = 3–5). Error bars indicate s.e.m.
(TIF)
Figure S7 Induction of IL-17A in BALB/c mice and additional
sources of IL-17A during exacerbations. (A) Proportion of IL-17A
positive CD3+ CD42 CD82 cdTCR2 cells or CD32 cells was
determined by flow cytometry after unspecific restimulation
in vitro. (B) IL-17A expression in BALB/c mice was assessed in
lung homogenate by quantitative real-time PCR and normalized
to GAPDH. All data are representative of two independent
experiments (n = 4–5) and mean 6 s.e.m. is shown.
(TIF)
Author Contributions
Conceived and designed the experiments: AS BJM LN. Performed the
experiments: AS KY AT OS. Analyzed the data: AS KY AT OS.
Contributed reagents/materials/analysis tools: YI. Wrote the paper: AS
BJM KY.
References
1. Barnes PJ (2004) Mediators of chronic obstructive pulmonary disease.
Pharmacol Rev 56: 515–548.
2. Donaldson GC, Wedzicha JA (2006) COPD exacerbations.1: Epidemiology.
Thorax 61: 164–168.
3. Sethi S, Mallia P, Johnston SL (2009) New paradigms in the pathogenesis of
chronic obstructive pulmonary disease II. Proc Am Thorac Soc 6: 532–534.
4. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E,
Navarro M, et al. (2005) Severe acute exacerbations and mortality in patients
with chronic obstructive pulmonary disease. Thorax 60: 925–931.
5. Suissa S, Dell’aniello S, Ernst P (2012) Long-term natural history of chronic
obstructive pulmonary disease: severe exacerbations and mortality. Thorax.
6. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, et al. (1998)
Effect of exacerbation on quality of life in patients with chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 157: 1418–1422.
7. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, et al. (2006)
Infections and airway inflammation in chronic obstructive pulmonary disease
severe exacerbations. Am J Respir Crit Care Med 173: 1114–1121.
8. Rohde G, Wiethege A, Borg I, Kauth M, Bauer TT, et al. (2003) Respiratory
viruses in exacerbations of chronic obstructive pulmonary disease requiring
hospitalisation: a case-control study. Thorax 58: 37–42.
9. Hurst JR, Donaldson GC, Wilkinson TM, Perera WR, Wedzicha JA (2005)
Epidemiological relationships between the common cold and exacerbation
frequency in COPD. Eur Respir J 26: 846–852.
10. Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, et al. (2001)
Respiratory viruses, symptoms, and inflammatory markers in acute exacerba-
tions and stable chronic obstructive pulmonary disease. Am J Respir Crit Care
Med 164: 1618–1623.
11. Wedzicha JA (2004) Role of viruses in exacerbations of chronic obstructive
pulmonary disease. Proc Am Thorac Soc 1: 115–120.
12. Potena A, Caramori G, Casolari P, Contoli M, Johnston SL, et al. (2007)
Pathophysiology of viral-induced exacerbations of COPD. Int J Chron Obstruct
Pulmon Dis 2: 477–483.
13. Ko FW, Ip M, Chan PK, Chan MC, To KW, et al. (2007) Viral etiology of acute
exacerbations of COPD in Hong Kong. Chest 132: 900–908.
14. Tan WC, Xiang X, Qiu D, Ng TP, Lam SF, et al. (2003) Epidemiology of
respiratory viruses in patients hospitalized with near-fatal asthma, acute
exacerbations of asthma, or chronic obstructive pulmonary disease. Am J Med
115: 272–277.
15. Qiu Y, Zhu J, Bandi V, Atmar RL, Hattotuwa K, et al. (2003) Biopsy
neutrophilia, neutrophil chemokine and receptor gene expression in severe
Viral Exacerbation of Chronic Lung Inflammation
PLOS ONE | www.plosone.org 10 June 2014 | Volume 9 | Issue 6 | e98440
exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care
Med 168: 968–975.
16. Aaron SD, Angel JB, Lunau M, Wright K, Fex C, et al. (2001) Granulocyte
inflammatory markers and airway infection during acute exacerbation of chronic
obstructive pulmonary disease. Am J Respir Crit Care Med 163: 349–355.
17. Gessner C, Scheibe R, Wotzel M, Hammerschmidt S, Kuhn H, et al. (2005)
Exhaled breath condensate cytokine patterns in chronic obstructive pulmonary
disease. Respir Med 99: 1229–1240.
18. Bathoorn E, Kerstjens H, Postma D, Timens W, MacNee W (2008) Airways
inflammation and treatment during acute exacerbations of COPD. Int J Chron
Obstruct Pulmon Dis 3: 217–229.
19. Bauer CM, Zavitz CC, Botelho FM, Lambert KN, Brown EG, et al. (2010)
Treating viral exacerbations of chronic obstructive pulmonary disease: insights
from a mouse model of cigarette smoke and H1N1 influenza infection. PLoS
One 5: e13251.
20. Botelho FM, Bauer CM, Finch D, Nikota JK, Zavitz CC, et al. (2011) IL-
1alpha/IL-1R1 expression in chronic obstructive pulmonary disease and
mechanistic relevance to smoke-induced neutrophilia in mice. PLoS One 6:
e28457.
21. Churg A, Zhou S, Wang X, Wang R, Wright JL (2009) The role of interleukin-
1beta in murine cigarette smoke-induced emphysema and small airway
remodeling. Am J Respir Cell Mol Biol 40: 482–490.
22. Couillin I, Vasseur V, Charron S, Gasse P, Tavernier M, et al. (2009) IL-1R1/
MyD88 signaling is critical for elastase-induced lung inflammation and
emphysema. J Immunol 183: 8195–8202.
23. Doz E, Noulin N, Boichot E, Guenon I, Fick L, et al. (2008) Cigarette smoke-
induced pulmonary inflammation is TLR4/MyD88 and IL-1R1/MyD88
signaling dependent. J Immunol 180: 1169–1178.
24. Lappalainen U, Whitsett JA, Wert SE, Tichelaar JW, Bry K (2005) Interleukin-
1beta causes pulmonary inflammation, emphysema, and airway remodeling in
the adult murine lung. Am J Respir Cell Mol Biol 32: 311–318.
25. Lucey EC, Keane J, Kuang PP, Snider GL, Goldstein RH (2002) Severity of
elastase-induced emphysema is decreased in tumor necrosis factor-alpha and
interleukin-1beta receptor-deficient mice. Lab Invest 82: 79–85.
26. Pauwels NS, Bracke KR, Dupont LL, Van Pottelberge GR, Provoost S, et al.
(2011) Role of IL-1alpha and the Nlrp3/caspase-1/IL-1beta axis in cigarette
smoke-induced pulmonary inflammation and COPD. Eur Respir J 38: 1019–
1028.
27. Castro P, Legora-Machado A, Cardilo-Reis L, Valenca S, Porto LC, et al. (2004)
Inhibition of interleukin-1beta reduces mouse lung inflammation induced by
exposure to cigarette smoke. Eur J Pharmacol 498: 279–286.
28. Kersul AL, Iglesias A, Rios A, Noguera A, Forteza A, et al. (2011) Molecular
mechanisms of inflammation during exacerbations of chronic obstructive
pulmonary disease. Arch Bronconeumol 47: 176–183.
29. Kythreotis P, Kokkini A, Avgeropoulou S, Hadjioannou A, Anastasakou E, et al.
(2009) Plasma leptin and insulin-like growth factor I levels during acute
exacerbations of chronic obstructive pulmonary disease. BMC Pulm Med 9: 11.
30. Horai R, Asano M, Sudo K, Kanuka H, Suzuki M, et al. (1998) Production of
mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta,
and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-
induced fever development and glucocorticoid secretion. J Exp Med 187: 1463–
1475.
31. Thurlbeck WM (1967) Measurement of pulmonary emphysema. Am Rev Respir
Dis 95: 752–764.
32. Saetta M, Shiner RJ, Angus GE, Kim WD, Wang NS, et al. (1985) Destructive
index: a measurement of lung parenchymal destruction in smokers. Am Rev
Respir Dis 131: 764–769.
33. Uyttenhove C, Van Snick J (2006) Development of an anti-IL-17A auto-vaccine
that prevents experimental auto-immune encephalomyelitis. Eur J Immunol 36:
2868–2874.
34. Sajjan U, Ganesan S, Comstock AT, Shim J, Wang Q, et al. (2009) Elastase- and
LPS-exposed mice display altered responses to rhinovirus infection. Am J Physiol
Lung Cell Mol Physiol 297: L931–944.
35. Hasday JD, Bascom R, Costa JJ, Fitzgerald T, Dubin W (1999) Bacterial
endotoxin is an active component of cigarette smoke. Chest 115: 829–835.
36. Larsson L, Szponar B, Pehrson C (2004) Tobacco smoking increases
dramatically air concentrations of endotoxin. Indoor Air 14: 421–424.
37. Gaschler GJ, Zavitz CC, Bauer CM, Stampfli MR (2010) Mechanisms of
clearance of nontypeable Haemophilus influenzae from cigarette smoke-exposed
mouse lungs. Eur Respir J 36: 1131–1142.
38. Han Y, Ling MT, Mao H, Zheng J, Liu M, et al. (2014) Influenza virus-induced
lung inflammation was modulated by cigarette smoke exposure in mice. PLoS
One 9: e86166.
39. Daffern PJ, Jagels MA, Hugli TE (1999) Multiple epithelial cell-derived factors
enhance neutrophil survival. Regulation by glucocorticoids and tumor necrosis
factor-alpha. Am J Respir Cell Mol Biol 21: 259–267.
40. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M (2012) IL-6/IL-6
receptor system and its role in physiological and pathological conditions. Clin Sci
(Lond) 122: 143–159.
41. Di Stefano A, Caramori G, Gnemmi I, Contoli M, Vicari C, et al. (2009) T
helper type 17-related cytokine expression is increased in the bronchial mucosa
of stable chronic obstructive pulmonary disease patients. Clin Exp Immunol 157:
316–324.
42. Doe C, Bafadhel M, Siddiqui S, Desai D, Mistry V, et al. (2010) Expression of
the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD.
Chest 138: 1140–1147.
43. Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, et al. (2009) Critical
regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity
30: 576–587.
44. Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC (2006) A crucial role for
interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate
autoimmune encephalomyelitis. J Exp Med 203: 1685–1691.
45. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, et al. (2009)
Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T
cells, amplifying Th17 responses and autoimmunity. Immunity 31: 331–341.
46. Wedzicha JA, Seemungal TA (2007) COPD exacerbations: defining their cause
and prevention. Lancet 370: 786–796.
47. Hoogendoorn M, Hoogenveen RT, Rutten-van Molken MP, Vestbo J, Feenstra
TL (2011) Case fatality of COPD exacerbations: a meta-analysis and statistical
modelling approach. Eur Respir J 37: 508–515.
48. Balbi B, Bason C, Balleari E, Fiasella F, Pesci A, et al. (1997) Increased
bronchoalveolar granulocytes and granulocyte/macrophage colony-stimulating
factor during exacerbations of chronic bronchitis. Eur Respir J 10: 846–850.
49. Drost EM, Skwarski KM, Sauleda J, Soler N, Roca J, et al. (2005) Oxidative
stress and airway inflammation in severe exacerbations of COPD. Thorax 60:
293–300.
50. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA (2000)
Time course and recovery of exacerbations in patients with chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 161: 1608–1613.
51. Hacievliyagil SS, Gunen H, Mutlu LC, Karabulut AB, Temel I (2006)
Association between cytokines in induced sputum and severity of chronic
obstructive pulmonary disease. Respir Med 100: 846–854.
52. Chen K, Pociask DA, McAleer JP, Chan YR, Alcorn JF, et al. (2011) IL-17RA is
required for CCL2 expression, macrophage recruitment, and emphysema in
response to cigarette smoke. PLoS One 6: e20333.
53. Shan M, Yuan X, Song LZ, Roberts L, Zarinkamar N, et al. (2012) Cigarette
smoke induction of osteopontin (SPP1) mediates T(H)17 inflammation in human
and experimental emphysema. Sci Transl Med 4: 117ra119.
54. Crowe CR, Chen K, Pociask DA, Alcorn JF, Krivich C, et al. (2009) Critical role
of IL-17RA in immunopathology of influenza infection. J Immunol 183: 5301–
5310.
55. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, et al. (2003)
Maintenance therapy with budesonide and formoterol in chronic obstructive
pulmonary disease. Eur Respir J 22: 912–919.
56. Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, et al.
(2009) Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalk-
ane pressurized metered-dose inhaler in patients with chronic obstructive
pulmonary disease: results from a 1-year randomized controlled clinical trial.
Drugs 69: 549–565.
57. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, et al. (2003) Efficacy
and safety of budesonide/formoterol in the management of chronic obstructive
pulmonary disease. Eur Respir J 21: 74–81.
58. Barnes PJ (2010) Medicine. Neutrophils find smoke attractive. Science 330: 40–
41.
59. Perttunen H, Moilanen E, Zhang X, Barnes PJ, Kankaanranta H (2008) Beta2-
agonists potentiate corticosteroid-induced neutrophil survival. COPD 5: 163–
169.
Viral Exacerbation of Chronic Lung Inflammation
PLOS ONE | www.plosone.org 11 June 2014 | Volume 9 | Issue 6 | e98440
